MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Sarepta Therapeutics Inc

Ouvert

SecteurSoins de santé

61.06 1.01

Résumé

Variation du prix de l'action

24h

Actuel

Min

59.75

Max

61.86

Chiffres clés

By Trading Economics

Revenu

125M

159M

Ventes

191M

658M

P/E

Moyenne du Secteur

23.603

57.333

BPA

1.9

Marge bénéficiaire

24.156

Employés

1,372

EBITDA

138M

187M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+140.04% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-5.3B

5.4B

Ouverture précédente

60.05

Clôture précédente

61.06

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Sarepta Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mars 2025, 14:19 UTC

Principaux Mouvements du Marché

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20 juin 2024, 23:05 UTC

Principaux Mouvements du Marché

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21 juin 2024, 08:58 UTC

Actualités

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Comparaison

Variation de prix

Sarepta Therapeutics Inc prévision

Objectif de Prix

By TipRanks

140.04% hausse

Prévisions sur 12 Mois

Moyen 148.25 USD  140.04%

Haut 209 USD

Bas 70 USD

Basé sur 22 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

22 ratings

18

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

59.31 / 62.78Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.